MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a biopharmaceutical company founded in 2018 and headquartered in Foster City, California. The company went public in July 2019 and focuses on developing and commercializing novel therapies for rare and orphan diseases, particularly those affecting the liver and bile acid metabolism. Since its inception, Mirum has transformed from a clinical-stage company into a commercial-stage biopharmaceutical enterprise with multiple approved products and a growing pipeline of investigational therapies targeting underserved patient populations with debilitating rare diseases.